Current Treatment for Mycoplasma genitalium in a Woman in Michigan
For a symptomatic woman with confirmed M. genitalium infection in Michigan, treat with doxycycline 100 mg orally twice daily for 7 days followed immediately by azithromycin 1 g on day 1, then 500 mg daily on days 2-4 (extended regimen). If macrolide resistance testing is available and shows resistance, or if the patient fails initial azithromycin-based therapy, use moxifloxacin 400 mg orally once daily for 7 days (or 14 days for complicated infections like pelvic inflammatory disease) 1, 2, 3.
Treatment Algorithm
First-Line Therapy (Macrolide-Susceptible or Unknown Resistance)
- Doxycycline 100 mg orally twice daily for 7 days (lead-in to reduce organism load and decrease resistance selection)
- Followed immediately by azithromycin: 500 mg on day 1, then 250 mg daily on days 2-5 3
Second-Line Therapy (Macrolide-Resistant or Treatment Failure)
- Moxifloxacin 400 mg orally once daily for 7 days for uncomplicated infection 1, 3
- Moxifloxacin 400 mg orally once daily for 14 days for complicated infections (PID, cervicitis with upper tract involvement) 3
Third-Line Options (Refractory Cases)
- Doxycycline or minocycline 100 mg twice daily for 14 days (40-70% cure rate) 3
- Pristinamycin 1 g four times daily for 10 days (~75% cure rate, though availability in the U.S. is limited) 3
Critical Clinical Considerations
When to Test
Test women with:
- Persistent or recurrent cervicitis 1
- Pelvic inflammatory disease 1
- Sexual contacts of confirmed M. genitalium cases 1
Do NOT test asymptomatic women without known exposure, including pregnant women, as this leads to inappropriate antibiotic use 1.
Resistance Testing Reality
While resistance-guided therapy is strongly recommended, macrolide resistance testing is not FDA-approved and remains largely unavailable in routine U.S. practice 1. Fluoroquinolone resistance testing is even less accessible 4. Given that more than 50% of M. genitalium infections now carry macrolide resistance 2, this creates a significant clinical challenge.
In Michigan, where resistance testing is likely unavailable, the practical approach is:
- Start with doxycycline-azithromycin for initial treatment
- If treatment fails, assume macrolide resistance and switch to moxifloxacin 1
Common Pitfalls to Avoid
Do not use single-dose azithromycin 1 g alone - this was the older recommendation but leads to treatment failure and resistance development 3, 5. The extended regimen with doxycycline lead-in is now standard.
Do not use doxycycline monotherapy - cure rates are only 30-40%, though it remains valuable as part of combination therapy 3.
Avoid moxifloxacin overuse - fluoroquinolone resistance is rising, and moxifloxacin carries FDA warnings for serious adverse effects 3. Reserve it for documented macrolide resistance or treatment failures.
Pregnancy Considerations
If the patient is pregnant, azithromycin is the only recommended option (extended regimen: 500 mg day 1, then 250 mg days 2-5). Moxifloxacin is contraindicated in pregnancy 6. Doxycycline should be avoided after the first trimester.
Follow-Up and Partner Management
- Instruct the patient to abstain from sexual intercourse for 7 days after completing therapy
- All sexual partners from the past 60 days require evaluation and treatment 7
- Test of cure is not routinely recommended unless symptoms persist 2
- Do not retreat based on symptoms alone without documented evidence of persistent infection 7
Evidence Quality Note
The 2010 CDC guidelines 7 are outdated and predate widespread recognition of macrolide resistance. Current management relies on more recent research evidence 4, 1, 2, 3 showing the critical importance of resistance-guided therapy and extended azithromycin regimens. The European guideline from 2021 3 provides the most comprehensive contemporary treatment framework, though U.S. clinicians face greater challenges due to limited resistance testing availability 1.